Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Javier Pedreño"'
Autor:
Yvette Rabadà, Oriol Bosch-Sanz, Xevi Biarnés, Javier Pedreño, Luis Caveda, David Sánchez-García, Jordi Martorell, Mercedes Balcells
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7002 (2024)
A new family of antifibrinolytic drugs has been recently discovered, combining a triazole moiety, an oxadiazolone, and a terminal amine. Two of the molecules of this family have shown activity that is greater than or similar to that of tranexamic aci
Externí odkaz:
https://doaj.org/article/a69d290e77854b9bb47efb4136b92769
Autor:
Oriol Bosch-Sanz, Yvette Rabadà, Xevi Biarnés, Javier Pedreño, Luis Caveda, Mercedes Balcells, Jordi Martorell, David Sánchez-García
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 23, p 14942 (2022)
Fibrinolysis is a natural process that ensures blood fluidity through the removal of fibrin deposits. However, excessive fibrinolytic activity can lead to complications in different circumstances, such as general surgery or severe trauma. The current
Externí odkaz:
https://doaj.org/article/e54f1207d9e840dba8444d8babf9fe95
Autor:
Xavier Biarnés Fontal, Noemí Balà Palasí, David Sánchez García, Mercedes Balcells Camps, Jordi Martorell López, Francisco Javier Pedreño Egea, Oriol Bosch Sanz
Publikováno v:
The 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery.
Autor:
M. Pino, Javier Pedreño, Gines Escolar, Maria Rosa Hernandez, Gemma Arderiu, Raul Tonda, Eduardo Salas, Mireia Serradell
Publikováno v:
Journal of Cardiovascular Medicine. 7:859-865
Licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) has been demonstrated to inhibit cyclooxygenase (COX)-1, COX-2, and 5-lipoxygenase. The aim of this study was to investigate the in-vitro effects of l
Publikováno v:
Atherosclerosis. 155:99-112
We present evidence of a link between low-density lipoprotein (LDL) receptor binding and activation of a platelet G-coupled protein. LDL stimulation induced cytosolic [Ca 2+ ] i mobilization, increase in inositol 1,4,5-triphosphate (IP 3 ) formation
Autor:
Javier Pedreño, Silvia Paredes, Germán Camejo, Eva Hurt-Camejo, Lluís Masana, Pere Benito, Joan-Carles Vallvé, Birgitta Rosengren, Peter Sartipy, Olov Wiklund
Publikováno v:
Arthritis & Rheumatism. 44:2761-2767
Objective. This work studied the presence of inflammatory and atherogenic lipoprotein markers that could explain the high incidence of cardiovascular disease (CVD) reported in rheumatoid arthritis (RA) patients. Methods. Inflammatory markers were 1)
Publikováno v:
Atherosclerosis. 154:23-29
Early studies considered that fibrinogen receptor (glycoprotein [GP] IIb–IIIa or platelet integrin α IIb β 3 ) is the binding site for low-density lipoprotein (LDL) and high-density lipoprotein type 3 (HDL 3 ). Recent data, however, do not suppor
Autor:
Agustı́ Jornet, Jaume Canela, Alfons Ballester, Mariano Uson, Javier Pedreño, Rosa Fernández, Marius Petit
Publikováno v:
International Journal of Cardiology. 74:159-167
Multiple studies have demonstrated that elevated serum lipoprotein (a) [Lp(a)] levels are independent predictors for coronary artery disease (CAD) in subjects without diabetes mellitus (DM). However, their contribution in patients with DM is controve
Publikováno v:
Thrombosis Research. 94:33-44
The mechanisms for regulating platelet HDL3 binding sites were investigated. HDL3 binding was rapid (T1/2 association=4 minutes) and completely reversible (T1/2 dissociation=14.5 minutes) at 4°C, 22°C, and 37°C, and kinetic analysis yielded forwar
Publikováno v:
Scopus-Elsevier
BACKGROUND It is speculated that, as a result of its tissue selectivity, pravastatin may be a safer drug than the lipophilic 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors in combination therapy involving drugs with potential mu